IRMA(IMATINIB RESISTANCE MUTATION ANALYSIS)IN CML

This test is useful for detecting over 90 known and novel mutations in ABL kinase domain of Ph chromosome including T3151 and P-loop mutations responsible for resistance to Imatinib in CML patients. Imatinib is a Tyrosine kinase inhibitor (TKI) which helps in overcoming mutations to aid in the treatment of CML.


How to prepare for the test?

Submit latest BCR-ABL Quantitative report along with sample.

Book Your Test

*All fields are mandatory.
Home sample collection charges will be applicable.